TIDMAVO

RNS Number : 3945B

Advanced Oncotherapy PLC

30 September 2022

30 September 2022

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Total Voting Rights

Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation proton therapy system for cancer treatment, announces that the Company's issued share capital as at the date of this announcement comprises 507,231,209 ordinary shares of 25p each, with one voting right per share ("Ordinary Shares"). The Company does not hold any ordinary shares in treasury and therefore the total number of Ordinary Shares with voting rights in the Company is 507,231,209. This announcement is required to be made at month end in accordance with the FCA's Disclosure Guidance and Transparency Rules.

 
 Advanced Oncotherapy plc                                          www.avoplc.com 
 Dr. Michael Sinclair, Executive Chairman               Tel: +44 (0) 20 3617 8728 
 Nicolas Serandour, CEO 
 
 Allenby Capital Limited (Nomad and 
  Joint Broker) 
 Nick Athanas / Piers Shimwell (Corporate               Tel: +44 (0) 20 3328 5656 
  Finance) 
  Amrit Nahal / Matt Butlin (Sales 
  and Corporate Broking) 
 
 SI Capital Ltd (Joint Broker) 
 Nick Emerson                                           Tel: +44 (0) 1483 413 500 
 Jon Levinson                                           Tel: +44 (0) 20 3871 4066 
 
 FTI Consulting (Financial PR & IR)         advancedoncotherapy@fticonsulting.com 
 Simon Conway / Rob Winder                              Tel: +44 (0) 20 3727 1000

About Advanced Oncotherapy Plc

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREAANEDDKAEFA

(END) Dow Jones Newswires

September 30, 2022 12:00 ET (16:00 GMT)

Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Advanced Oncotherapy Charts.
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Advanced Oncotherapy Charts.